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Abstract
Objectives: To assess the clinical efficacy of renal artery denervation (RAD) in our center and to
compare the efficacy of two different radiofrequency (RF) systems.
Background: Several systems are available for RF renal denervation. Whether there is a differ-
ence in clinical efficacy among various systems remains unknown.
Methods: Renal artery denervation was performed on 43 patients with resistant hypertension
using either the single electrode Symplicity Flex (n = 20) or the multi-electrode EnligHTN sys-
tem (n = 23). Median post-procedural follow-up was 32.93 months. The primary outcome was
post-procedural change in office blood pressure (BP) within 1 year (short-term follow-up). Sec-
ondary outcomes were change in office BP between 1 and 4 years (long-term follow-up) and
the difference in office BP reduction between the two systems at each follow-up period.
Results: For the total cohort, mean baseline office BP (systolic/diastolic) was 174/94 mmHg. At
follow-up, mean changes in office BP from baseline were −19.70/−11.86 mmHg (P < 0.001) and
−21.90/−13.94 mmHg (P < 0.001) for short-term and long-term follow-up, respectively. The differ-
ences in office BP reduction between Symplicity and EnligHTN groups were 8.96/1.23 mmHg
(P = 0.42 for systolic BP, P = 0.83 for diastolic BP) and 9.56/7.68 mmHg (P = 0.14 for systolic BP,
P = 0.07 for diastolic BP) for short-term and long-term follow-up, respectively.
Conclusions: In our cohort, there was a clinically significant office BP reduction after RAD,
which persisted up to 4 years. No significant difference in office BP reduction between the two
systems was found.
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1 | INTRODUCTION
The initial renal artery denervation (RAD) trials demonstrated signifi-
cant blood pressure (BP) reduction, which persisted up to 3 years.1–3
However, the randomized sham-controlled trial (Symplicity HTN-3)
showed no significant difference in BP reduction between the RAD
and the sham control arm.4 Inexperienced operators in RAD and lack
of bilateral circumferential denervation in most cases were possible
reasons for insufficient denervation in Symplicity HTN-3.5,6 Since its
first clinical application, RAD technology has evolved rapidly in con-
sideration to different ablation modalities and energy delivery
methods.7 Systems that utilize radiofrequency (RF) energy remain the
most commonly used. Positive results were reported using both single
electrode Symplicity Flex (Medtronic, Minneapolis, MN, USA) and
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multi-electrode EnligHTN (Abbott, Chicago, IL, USA) RF systems.3,8–10
Nonetheless, studies on the clinical efficacy of single electrode versus
multi-electrode systems have not been published. We previously com-
pared the single electrode Symplicity Flex versus the multi-electrode
EnligHTN in a gel based phantom renal artery model that allowed the
spatiotemporal assessment of thermodynamics and lesion dimensions
produced by each system.11 In the gel model, Symplicity Flex pro-
duced larger lesions compared to EnligHTN. While the difference in
lesion size was statistically significant, it was unclear if that difference
would be clinically relevant. Moreover, it has been suggested that
functional and anatomical reinnervation after RF renal denervation
can occur and is likely to be complete by 11 months post procedure.12
Therefore, we aimed to assess the efficacy of RAD in reducing office
BP for a cohort of patients with refractory hypertension who under-
went RAD using two RF systems (single electrode Symplicity Flex or
multi-electrode EnligHTN system) within 1 year (short-term follow
up), and to determine if BP reduction is persistent in the longer-term
(between 1 and 4 years; long-term follow up) beyond the suggested
time for reinnervation. We also aimed to compare office BP reduction
between those two systems at each follow-up period.
2 | METHODS
We prospectively collected data for a total of 43 patients in whom
RAD procedure was performed at our center between 2012 and
2015. Symplicity Flex was used in the first 20 consecutive patients,
while EnligHTN was used in the subsequent 23 cases. Human Ethics
Research Committee at Westmead Hospital approved the study and a
written informed consent was obtained from all patients.
2.1 | Study population
Patients were referred for the procedure after an initial assessment by
their treating cardiologist or nephrologist. Referral criteria included
average baseline office systolic blood pressure (SBP) of ≥150 mmHg
while on a minimum of three antihypertensive medications, or those
with office SBP > 140 mmHg and intolerant to antihypertensive med-
ications or had recurrent admissions with malignant hypertension. All
patients reported compliance to their antihypertensive medications.
They all had a CT renal angiogram prior to the procedure for anatomi-
cal assessment of their renal arteries and to exclude adrenal adeno-
mas. Patients were excluded if they had significant bilateral renal
artery stenosis, bilateral renal artery stenting or a small renal artery
diameter (<4 mm) bilaterally. Also, those with a secondary cause of
hypertension were excluded.
Renal artery tortuosity index was calculated for each patient using
the arc: chord ratio method, as described previously.13
2.2 | Renal artery denervation procedure
Renal artery denervation procedures were performed by an interven-
tional cardiologist and a vascular surgeon, under conscious intrave-
nous sedation using midazolam and fentanyl. Intra-arterial Heparin
was administered in all cases at a dose of 50 units/kg. A 6 Fr
(Symplicity) or 8 Fr (EnligHTN) sheaths were introduced into the right
femoral artery for access. Selective right and left renal arteriograms
using a 6 Fr LIMA guiding catheter (Symplicity) or an 8 Fr EnligHTN
guiding catheter (EnligHTN) were performed to assess vessel anatomy
for denervation suitability. Prior to RF application, a 200 mcg bolus of
glyceryl trinitrate was administered into each renal artery to prevent
arterial spasm. Radiofrequency ablations in a spiral fashion were deliv-
ered into each renal artery wall starting distally and using the clinically
recommended settings for both systems (Table 1). A final arteriogram
was performed at the end of ablation to exclude complications includ-
ing severe spams, perforation, or dissection. The femoral arterial
access site was closed with a ProGlide closure device if suitable. The
following day, patients were reviewed for any adverse events or com-
plications and discharged home if well. All patients were advised to
continue the same antihypertensive medications, unless advised oth-
erwise by their treating cardiologist or nephrologist.
2.3 | Follow-up
Data including office BP, antihypertensive medications, and adverse
events including dizziness or postural hypotension, readmission with
malignant hypertension, stroke or transient ischemic attack (TIA), car-
diac events and all-cause mortality were collected through phone
communication with patients or from clinic and medical record review.
Each patient had multiple follow-ups to record BP measurements at
different time-points. Office BP measurements were recorded by the
treating doctors on follow-up. Mean office BP was determined during
the short-term and long-term follow-up periods for each patient.
2.4 | Outcomes
The primary endpoint was overall change in office BP from baseline in
the short-term follow-up. Secondary outcomes included; change in
office BP in the long-term follow-up and the difference in office BP
reduction between the Symplicity and the EnligHTN groups during
the two follow-up periods. Secondary outcomes relating to safety
included periprocedural complications and long-term adverse events
(cardiac events, stroke or TIA, and death from any cause).
2.5 | Statistical analysis
Statistical analyses were performed in SPSS 24 (IBM Corp., Armonk,
NY, USA) and S-PLUS 8.2 (TIBCO software Inc., Palo Alto, CA, USA)
TABLE 1 Summary of the clinical parameters for the Symplicity and
EnligHTN renal denervation systems
System parameters Symplicity EnligHTN
Monitoring Temperature and
impedance based
algorithm
Temperature
controlled
algorithm
Number of electrodes 1 4
Maximal power delivered (W) 8 6
Maximal temperature
at electrode tip (C)
70 75
Duration of each
ablation (sec)
120 90
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statistical software. Baseline characteristic for the two groups were
compared using independent sample t-tests for continuous variables
and Chi Square tests for categorical variables. Two-tailed tests with a
significance level of 5% were used throughout. Data for baseline char-
acteristics were expressed as the mean  standard deviation.
Linear mixed effect models were used to investigate the changes
in SBP and diastolic blood pressure (DBP) post procedure during
short-term and long-term follow-up periods, and to test for associa-
tion (interaction) between the effect of time (three-level factor, pre-
op baseline, short-term follow-up and long-term follow-up) and sys-
tem (two-level factor). Linear mixed effect models were also used to
test for association between the effect of time and each of the base-
line or procedural covariates including baseline SBP, heart rate, body
mass index (BMI), ablation time, ablation number, and tortuosity index.
Patient identifier was considered as a random effect and the time fac-
tor as both a fixed effect and as a random effect with a general posi-
tive definite covariance structure. The procedural or baseline
covariates and their two-way interactions with the time factor were
considered as fixed effects. Parameter estimates (estimated mean)
and their 95% confidence intervals (95% CI) were used to quantify the
changes observed in both follow-up periods.
3 | RESULTS
3.1 | Study population
The study population baseline characteristics are summarized in
Table 2. A total of 43 patients were followed up for a median of
32.93 months (IQR 29.43–42.87). For the total cohort, mean baseline
office SBP was 174  20 mmHg and mean baseline office DBP was
94  16 mmHg. There was no significant difference in baseline office
BP between the Symplicity and EnligHTN groups (Table 1). In both
groups, patient enrolment rates were greater for males than females
but not significantly different between groups (P = 0.4). Overall, there
was no significant difference in baseline characteristics including risk
factors between the two groups.
3.2 | Procedural parameters
Based on anatomical variation including vessel length and diameter,
4–12 RF ablations were delivered into each renal artery. Total abla-
tion duration was similar between the two groups despite the lon-
ger duration per ablation with Symplicity system. This was due to
the overall greater number of ablations in the EnligHTN group com-
pared to Symplicity (Table 3). Four patients in total had unilateral
denervation (one from the Symplicity group and three from the
EnligHTN group). Reasons for unilateral denervation included diffi-
cult anatomy with failure to engage the vessel (n = 1), presence of
previous renal artery stent unilaterally (n = 1), and a small renal
artery diameter (≤3.5 mm) on one side (n = 2). Accessory renal
arteries were present in five patients (one from the Symplicity
group and four from the EnligHTN group). No ablation was per-
formed in accessory renal arteries. Table 3 summarizes the proce-
dural parameters for both groups.
3.3 | Antihypertensive medications
The average number of antihypertensive medications for the total cohort
at baseline was 5.33  1.90 with no difference between the groups
(Table 1). At follow-up, the average number of antihypertensive medica-
tions was 5.14  2.05 (5.56  2.31 versus 4.22  0.83 for Symplicity
and EnligHTN respectively, P = 0.04) and 4.56  1.87 (4.80  2.30 ver-
sus 4.33  1.37 for Symplicity and EnligHTN, respectively, P = 0.75) for
short-term and long-term follow-up, respectively (Figure 1A).
TABLE 2 Summary of baseline characteristics for both Symplicity and
EnligHTN groups
Baseline
characteristics
Symplicity
(n = 20)
EnligHTN
(n = 23) P-value
Age (years) 63.05  9.64 65.17  7.99 0.43
Gender-male (%) 13 (65%0.00) 13 (56.52%) 0.57
Baseline SBP (mmHg) 177.08  21.15 171.13  19.75 0.35
Baseline DBP
(mmHg)
96.70  11.92 92.52  18.55 0.39
Number of BP
medications
at baseline
5.75  2.15 4.96  1.59 0.17
• BB 70.00% 60.90%
• CCB 75.00% 69.50%
• ACEi 50.00% 43.50
• ARB 95.00% 73.90%
• Thiazide 40.00% 52.20%
• Loop diuretics 40.00% 13.00%
• Vasodilators 35.00% 26.10%
• Centrally 60.00% 56.50%
• Aldosterone
antagonist
20.00% 17.40.3%
• Alpha blocker 45.00% 52.20%
Hyperlipidemia (%) 8 (40.00%) 11 (47.83%) 0.61
Smoking (%) 5 (25.00%) 5 (21.74%) 0.80
OSA (%) 7 (35.00%) 9 (39.13%) 0.78
IHD (%) 6 (30.00%) 8 (34.78%) 0.74
Stroke or TIA (%) 4 (20.00%) 5 (21.74%) 0.89
BMI (kg/m2) 34.15  8.64 32.65  7.37 0.54
eGFR
(ml/min/1.73 m2)
68.60  19.47 73.27  19.47 0.44
Abbreviations: ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BB,
beta blocker; BMI, body mass index; BP, blood pressure; CCB, calcium
channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomeru-
lar filtration rate; IHD, ischemic heart disease; OSA, obstructive sleep
apnea; SBP, systolic blood pressure; TIA, transient ischemic attack.
TABLE 3 Summary of procedural parameters for Symplicity and
EnligHTN groups
Procedural
parameters Symplicity (n = 20) EnligHTN (n = 23) p-value
Total ablation
time (min)
23.90  5.09 21.67  6.90 0.23
Number of ablations
per patient
11.95  2.54 19.00  7.06 <0.001
Accessory renal
artery (%)
1 (5%) 4 (17%) 0.21
Unilateral
denervation (%)
1 (5%) 3 (13%) 0.37
Tortuosity index 0.30  0.07 0.30  0.09 0.91
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In total, 33 patients (76.7%) had changes to their antihypertensive
medications by their final follow-up. Half of the patients (53.6%) had a
total decrease in medications number or dose, with or without class
change, five patients (11.6%) had an increase in the number of antihyper-
tensive medications, and five patients (11.6%) had a class change only.
3.4 | Outcomes
3.4.1 | Overall blood pressure reduction from baseline
For the entire study population, there was a significant reduction in both
systolic and diastolic office BP within all follow-up periods (Figure 1B,C).
Mean change in office BP from baseline was −19.70/−11.86 mmHg
(95% CI (SBP/DBP): [−30.08, −9.34]/[−17.14, −6.58], P < 0.001 for SBP
and DBP) and −21.90/−13.94 mmHg (95% CI: [−28.38, −15.43]/
[−17.14, −6.58], P < 0.001 for SBP and DBP) for short-term and long-
term follow-up, respectively.
No association between the change in office SBP and baseline or
procedural characteristics including heart rate, BMI, ablation duration,
ablation number, and tortuosity index was found (P = 0.33, 0.06, 0.17,
0.68, and 0.24 for association with each covariate, respectively). The
only significant association was seen between baseline office SBP and
the change in office SBP at 1 year (P < 0.001).
FIGURE 1 Number of antihypertensive medications per system at baseline and at each follow-up period (A). scatter plot of office BP at baseline
and both follow-up time points for the total cohort of patients, (B) SBP and (C) DBP. Change in BP from baseline for Symplicity and EnligHTN
groups at each follow-up time point, (D) SBP, (E) DBP
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3.4.2 | Blood pressure reduction per system
There was no significant difference in post-procedural BP change
between Symplicity and EnligHTN groups during any follow-up period
(difference of −8.96/−1.23 mmHg, 95% CI (SBP/DBP): [−30.86,
12.93]/[−12.61,10.16], P = 0.42 for SBP, P = 0.83 for DBP, and
−9.56/−7.68 mmHg, 95% CI: [−22.39, 3.27]/[−15.89,0.52], P = 0.14
for SBP, P = 0.07 for DBP), for short-term and long-term follow-up,
respectively (Figure 1D,E).
However, both systems were effective in reducing office BP. For
Symplicity group, mean change in office BP was −24.48/−13.5 mmHg
(95% CI: [−38.24, −10.71]/[−20.29, −6.63], P < 0.001 for SBP and
DBP) and −26.90/−17.92 mmHg (95% CI: [−36.14, −17.66]/[−23.85,
−11.98], P < 0.001 for SBP and DBP) for short-term and long-term
follow-up, respectively. With respect to the EnligHTN group, mean
change in office SBP was not statistically significant during the short-
term follow-up (−15.51 mmHg, 95% CI: [−32.53, 1.50], P = 0.07).
However, the change in office SBP became significant at the long-
term follow-up (−17.34 mmHg, 95% CI: [−26.23, −8.45], P < 0.001).
Mean change in office DBP was −12.23 mmHg (95% CI: [−15.90,
−4.56], P < 0.001) and −10.23 mmHg (95% CI: [−21.34, −3.12],
P = 0.01) for short-term and long-term follow-up, respectively.
3.4.3 | Safety outcomes
All RAD procedures were performed safely with no major procedural
complications. Minor complications included femoral hematoma man-
aged conservatively in three patients (7%) and transient contrast
nephropathy in a single patient who had mild renal impairment at
baseline. Eight patients reported symptoms of postural hypotension
on follow-up, and four patients had readmissions with hypertensive
episodes. There was one case of recurrent stroke at 9 months and
45 months. Three patients had hospital admission for myocardial
infarction and there were two mortalities of unknown cause. Table 4
summarizes procedural complications and adverse events for both
groups.
4 | DISCUSSION
In this study, RAD resulted in a significant BP reduction within the first
year, which persisted up to 4 years post procedure in our total cohort
of patients who underwent the procedure using two different RF sys-
tems. When assessing each treatment group independently, mean
reduction in office SBP from baseline was significant at all follow-up
periods for the Symplicity group. While mean reduction in office SBP
for the EnligHTN group did not achieve significance within the short-
term follow-up. A delayed effect on SBP occurred over the long-term
follow-up. This could be due to increased lesion depth achieved with
Symplicity Flex (3.8 mm) compared to EnligHTN (3.4 mm) as demon-
strated in our previous work using the phantom model, given that both
systems were tested under identical conditions including vessel diame-
ter, flow rate and with optimal electrode contact.11 Nonetheless, there
was no significant difference in office systolic or diastolic BP reduction
between the Symplicity and the EnligHTN group at any follow-up
period. The lack of significant between-group differences in BP reduc-
tion may suggest a class effect of various RAD devices, whereby ade-
quate injury to efferent and afferent nerve fibers was attained by both
systems. Alternatively, it could be explained by the small number of
patients in this study. Therefore, a larger study may be required in
order to detect significant differences between the two systems.
Notably, the reduction in BP was not associated with an increase
in the number of antihypertensive medications (Figure 1A). In fact,
half of the total cohort had a reduction to the number or the dose of
their antihypertensive medications. Thus, the BP reduction is unlikely
to be related to medications.
The Symplicity HTN-3 trial also used Symplicity Flex;4 however,
inadequate operator training and lack of experience in performing
RAD had resulted in a high failure rate for achieving bilateral circum-
ferential ablation (74% of cases).6 Therefore, it is likely that denerva-
tion in these cases was unsuccessful. While the Symplicity Flex may
deliver greater heat energy penetration, catheter manipulation to
achieve adequate contact and a circumferential ablation pattern is
technically challenging, and thus requires rigorous training and greater
operator experience compared to multi-electrode based systems. The
primary proceduralist in our study had extensive experience in RF
ablation and catheter manipulation.
Furthermore, it is still unclear what extent of denervation is
required to result in a desired clinical response. In a subset of patients
(n = 10) who underwent assessment of noradrenaline spillover
(marker for efferent sympathetic nerve activity) in the Symplicity
HTN-1 trial, there was a 47% reduction in noradrenaline spillover at
15–30 days post RAD, confirming the mechanistic effect of ablation
on suppression of sympathetic activity. Mean reduction in office BP at
6 months in this subgroup was 22/12 mmHg,1 suggesting that abla-
tion to achieve a target noradrenaline spillover of about 50% could be
TABLE 4 Summary of periprocedural complications and adverse events for each group
Complications and adverse events Symplicity EnligHTN Total p-value
Femoral hematoma 1 (5%) 2 (8.70%) 3 (7%) 0.64
Contrast nephropathy 0 1 (4.35) 1 (2.33) 0.35
Length of stay (days) 1.05  0.22 1.74  1.68 1.40  1.26 0.08
Postural hypotension 3 (15%) 5 (21.74%) 8 (18.60%) 0.57
Readmission with hypertension 2 (10%) 2 (8.70%) 4 (9.30%) 0.88
Cardiac events 3 (15%) 0 3 (7%) 0.05
Stroke or TIA 1 (5%) 0 1 (2.33%) 0.28
Mortality 0 2 (8.70%) 2 (4.65%) 0.17
Abbreviation: TIA, transient ischemic attack.
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an adequate endpoint of long-term functional denervation. A post-
mortem study demonstrated that for nerve fibers found within 10 mm
depth from the renal artery intima, between 50% and 75% of fibers
occurred at a depth between 2.44 and 4.28 mm in the main vessel.14
Therefore, both systems could cause injury to >50% but ≤75% of
nerves providing that ablation is performed optimally by ensuring con-
sistent electrode contact and energy delivery in a circumferential pat-
tern along the artery wall.
The newer multi-electrode Symplicity Spyral is likely to offer a
greater ablation consistency. However, it was found to have less heat-
ing depth than Symplicity Flex.15,16 Therefore, injury to 50% of nerve
fibers may not be achievable when ablation is performed in the main
vessel using Symplicity Spyral. Hence, RF ablation distal to the bifur-
cation in addition to the main vessel is now recommended when utiliz-
ing Symplicity Spyral, as nerve fibers are located closer to the intima
in the branches compared to the main vessel.14,16
Patient selection is another important factor that influences the
clinical efficacy of RAD. In our study, the only factor that was associ-
ated with BP response within 1 year was office SBP at baseline.
Nonetheless, it has become evident that patients with combined sys-
tolic and diastolic hypertension (SBP > 140 mmHg and DBP > 90
mmHg) respond better to RAD compared to those with isolated sys-
tolic hypertension (ISH).17,18 This is likely owing to the coexistence of
arterial stiffness in patients with ISH. Increased arterial stiffness as
measured by invasive pulse wave velocity was found to be a negative
predictor of denervation response.19 Nonetheless, when stratifying
patients with ISH according to their pulse wave velocity tertiles, those
in the low tertile were found to have significant BP reduction after
RAD, which was comparable to those with combined systolic and dia-
stolic hypertension.20 Therefore, arterial stiffness is likely to play a sig-
nificant role in confounding the outcomes of RAD in this subgroup of
patients, because the mechanism of hypertension may be complicated
by the influence of structurally mediated vascular dysfunction, rather
than, or in combination with vascular dysfunction mediated by sympa-
thetic overstimulation. Therefore, not all those with ISH should be
excluded from RAD.
Finally, as reported in major clinical trials our study illustrates that
RAD remains a safe procedure with low periprocedural complication
rates.
5 | LIMITATION
There are several limitations to our study. First, this was a non-
randomized comparison of a small patient cohort from a single center
without a sham control arm. However, the two groups were matched
in all baseline characteristics. In addition, the sham effect was absent
in recently published sham-controlled trials including the SPYRAL
HTN and RADIANCE-HTN SOLO.21–23 Second, no assessment of
ambulatory BP at baseline and at follow-ups was carried out, which
could lead to inclusion of patients with pseudoresistance and white-
coat syndrome. Furthermore, all Symplicity procedures were per-
formed first, followed by EnligHTN procedures consecutively. This
could lead to bias, favoring the EnligHTN system, as the proceduralist
was more experienced by that stage. Nonetheless, the primary
operator is an experienced interventionalist and electrophysiologist
who is very familiar with RF ablation.
Moreover, longer follow-up period was available for Symplicity
patients compared to EnligHTN. However, no difference in BP reduc-
tion was found between the two systems even when analysis was lim-
ited to 1 year. Finally, medication reduction during the study period
could potentially mask treatment effect. Therefore, it is difficult to
demonstrate superiority of one system over the other; however, this
study demonstrates non-inferiority.
6 | CONCLUSION
Although the two RAD systems did not differ significantly, they have
shown an overall reduction in office BP between selected timelines
compared to baseline measurements. Our study further supports
the role of RAD in treating appropriate patients with resistant
hypertension.
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